Skip to main content
UniHealth

Doctor search

Aparna Goel, MD

Internal Medicine · Stanford

NPI 1619104411

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
18
4 carriers
Offices
7

Offices

7 locations · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.

Plans that list them

18 plans · 4 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Goel’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

18 of 18 plans

Plans whose provider directory lists this clinician
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Silicon (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health smartHMO (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health the ONE (HMO)Alignment Health PlanListedOct 3, 2026
Anthem Full Dual Advantage Aligned (HMO D-SNP)Anthem Blue CrossListedOct 3, 2026
SCAN Balance (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
SCAN Classic (HMO)SCAN Health PlanListedOct 3, 2026
SCAN MyChoice (HMO)SCAN Health PlanListedOct 3, 2026
SCAN Strive (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
DualConnect (HMO D-SNP)Santa Clara Family Health PlanListedSep 1, 2026

California Medical Board record

Licence A114391 · Current

Licensed to practise in California · since 2010 · expires 2028-02-29 · Jefferson Medical College of Thomas Jefferson University.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
76.5 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Hospitals they work in

2 hospitals

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
    Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
  • Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend it
    Overall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths5.31 (4.24 to 6.37) · 8,661 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits14.1 (12.7 to 15.7) · 2,191 casesWorseJan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths4.08 (1.95 to 6.21) · 5,296 casesBetterJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.317BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.446BetterOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.241BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.7 (0.6 to 0.9) · 3,348 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.06 (0.45 to 1.67) · 5,374 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.86 (0.72 to 1)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths166.09 (137.88 to 194.3) · 470 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.1 · 192 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6.4 · 146 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths9.7 · 253 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.3 · 880 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 935 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.7 · 501 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.1 · 7,730 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.13 (0 to 0.27) · 20,799 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.28 (0.14 to 0.43) · 23,182 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.94 (0.2 to 1.68) · 5,694 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.36 (1.54 to 3.19) · 7,846 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.2 (3.76 to 6.64) · 5,603 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.38 (0.23 to 2.53) · 2,211 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.52 (0.21 to 0.83) · 19,915 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.6 · 416 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.869No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.857No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.368No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16.2 · 247 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.5 · 1,021 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits47.8 · 258 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-1.6 · 990 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits20.8 · 976 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.5 · 959 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.2 (4.4 to 6.2) · 2,191 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.1 · 425 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits9.6 · 158 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.6 · 183 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.7 (10.4 to 15.4) · 4,578 casesNo differentJan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Patient survey stars by topic at Stanford Health Care
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at Stanford Health Care
Room was "always" clean75%
Nurses "always" communicated well82%
Doctors "always" communicated well81%
Staff "always" explained63%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge89%
Doctors "always" explained things so they could understand76%
Doctors "always" listened carefully80%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)79%
Staff "always" explained new medications76%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully79%
Nurses "always" treated them with courtesy and respect88%
"Always" quiet at night53%
"YES", patients would definitely recommend the hospital83%
Staff "always" explained possible side effects50%
Yes, staff "did" give patients information about possible symptoms90%
See every measure and the patient survey for Stanford Health Care Tri-Valley

Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care Tri-Valley
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.178BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.237BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths0.79 (0 to 1.73) · 1,041 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.79 (0.5 to 1.08)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths145.81 (96.5 to 195.12) · 72 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths2.9 · 55 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths8.6 · 92 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths12.5 · 96 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths9.5 · 395 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 391 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths10.1 · 162 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths3 · 1,736 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.16 (0 to 0.37) · 4,425 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.22 (0.02 to 0.41) · 4,771 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths3.45 (1.46 to 5.44) · 1,403 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.5 (0.05 to 2.94) · 645 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths1.81 (0.38 to 3.24) · 1,279 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths8.53 (3.2 to 13.85) · 639 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.15 (1.89 to 8.41) · 648 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.61 (0.14 to 3.07) · 370 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.16 (0 to 0.83) · 4,160 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths4 · 74 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.369No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections1.112No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits13.1 · 110 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.1 · 437 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits-5.8 · 94 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-19.3 · 456 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits-0.3 · 402 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits15.8 · 358 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits6.8 (4.7 to 9.6) · 198 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits10.1 (7.5 to 13.6) · 198 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.3 · 80 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits10.9 · 46 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.3 · 92 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.4 (9.6 to 16.2) · 1,532 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits1 (0.8 to 1.2) · 929 casesNo differentJan 2024 – Dec 2024

What patients said (1,268 patients answered, 26% of those asked)

Patient survey stars by topic at Stanford Health Care Tri-Valley
Cleanliness3
Nurse communication3
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating3
Quietness2
Recommend hospital4
Share of patients giving the best answer at Stanford Health Care Tri-Valley
Room was "always" clean65%
Nurses "always" communicated well77%
Doctors "always" communicated well79%
Staff "always" explained58%
Yes, staff "did" give patients this information88%
Yes, staff "did" give patients information about help after discharge88%
Doctors "always" explained things so they could understand74%
Doctors "always" listened carefully78%
Doctors "always" treated them with courtesy and respect86%
Patients who gave a rating of "9" or "10" (high)70%
Staff "always" explained new medications72%
Nurses "always" explained things so they could understand73%
Nurses "always" listened carefully74%
Nurses "always" treated them with courtesy and respect84%
"Always" quiet at night42%
"YES", patients would definitely recommend the hospital74%
Staff "always" explained possible side effects44%
Yes, staff "did" give patients information about possible symptoms89%

Original Medicare doctor bills

$59,395

Medicare paid this office $59,395 for 251 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes35$15,072$106
Return visit (30+ min)75$10,652$100
Long return visit (40+ min)49$7,218$131
Initial hospital care with moderate level of medical decision making at least 75 minutes39$6,821$155
New patient visit (45+ min)19$2,472$130
See all 9 services
Every Original Medicare service billed
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes35$15,072$106
Return visit (30+ min)75$10,652$100
Long return visit (40+ min)49$7,218$131
Initial hospital care with moderate level of medical decision making at least 75 minutes39$6,821$155
New patient visit (45+ min)19$2,472$130
Hospital discharge day management, more than 30 minutes20$2,193$104
New patient visit (60+ min)11$1,820$165
Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope13$1,203$93
Measurement of liver stiffness41$388$9

Procedures Medicare counted

Procedure volume Medicare published
Colonoscopy14More than 44% of doctors who do this
Upper gastrointestinal (GI) endoscopy for acid reflux26More than 54% of doctors who do this

Who their Medicare patients are

251 Original Medicare patients in 2024. Average age 69 · Under 65 24% · 85 and older 5% · Women 57% · Also on Medicaid 38% · Health risk score 2.57. Above the middle of the specialty; the typical internal medicine clinician is at 1.76.

Conditions among them: High blood pressure 75% · Diabetes 43% · Chronic kidney disease 39% · Coronary heart disease 27% · Depression 22% · Heart failure 21% · Atrial fibrillation 20% · Cancer 13% · COPD 12% · Stroke 11% · Dementia 8%.

The office billed $368,673, Medicare allowed $78,044 and paid $59,395; for 558 services of 26 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
2024251558692.57$368,673$59,395
2023245696693.07$383,200$74,736
2022153285682.64$165,960$28,043
2021190445672.89$294,462$48,714
2020155354673.33$248,304$37,093
2019220568662.67$266,949$57,265
2018197474663.18$214,074$48,007
2017124311672.81$179,093$29,750
20162631622.62$17,271$3,631

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 12 services

Original Medicare services billed in 2023
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes62$30,716$110
Initial hospital care with moderate level of medical decision making at least 75 minutes59$10,497$159
Return visit (30+ min)56$5,682$79
Long return visit (40+ min)24$5,366$119
Long return visit (40+ min)26$4,247$121
New patient visit (60+ min)21$3,183$152
Hospital discharge day management, more than 30 minutes22$3,106$107
Return visit (30+ min)20$1,387$60
Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope13$1,359$105
New patient visit (45+ min)11$1,329$121
Measurement of liver stiffness31$299$9
Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito11$53$5

2022: 9 services

Original Medicare services billed in 2022
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes17$4,944$93
Initial hospital care with moderate level of medical decision making at least 75 minutes22$4,176$174
Return visit (30+ min)38$3,543$77
Long return visit (40+ min)12$3,267$131
New patient visit (60+ min)13$2,100$162
Return visit (30+ min)22$1,654$66
New patient visit (45+ min)12$1,449$121
Long return visit (40+ min)12$1,239$88
Measurement of liver stiffness22$212$10

2021: 11 services

Original Medicare services billed in 2021
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes40$11,646$95
Initial hospital care with moderate level of medical decision making at least 75 minutes31$6,846$185
Long return visit (40+ min)38$4,838$113
Return visit (30+ min)47$4,724$84
Long return visit (40+ min)20$4,118$125
New patient visit (60+ min)19$3,299$174
Return visit (30+ min)19$2,274$95
Hospital discharge day management, more than 30 minutes13$1,401$100
Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope11$1,118$102
Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope12$1,108$92
Measurement of liver stiffness12$113$9

2020: 7 services

Original Medicare services billed in 2020
Long return visit (40+ min)66$9,265$98
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes25$7,569$96
Long return visit (40+ min)27$4,251$92
Initial hospital care with moderate level of medical decision making at least 75 minutes18$3,524$185
New patient visit (60+ min)12$2,032$169
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes14$1,870$125
Hospital discharge day management, more than 30 minutes11$1,198$100

2019: 9 services

Original Medicare services billed in 2019
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes48$17,822$94
Long return visit (40+ min)60$10,614$95
Long return visit (40+ min)33$6,915$96
New patient visit (60+ min)34$4,814$142
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes22$2,967$124
Removal of polyps or growths of large bowel using an endoscope with mechanical snare11$2,579$234
Hospital discharge day management, more than 30 minutes12$1,124$94
Measurement of liver stiffness13$169$13
Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito18$87$5

2018: 10 services

Original Medicare services billed in 2018
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes58$17,589$94
Long return visit (40+ min)39$6,523$92
Long return visit (40+ min)31$4,085$110
New patient visit (60+ min)20$3,142$157
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes24$2,928$122
Initial hospital care with moderate level of medical decision making at least 75 minutes12$2,179$182
Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope13$1,426$110
Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope12$1,363$114
Hospital discharge day management, more than 30 minutes13$1,284$99
Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito14$67$4

2017: 7 services

Original Medicare services billed in 2017
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes28$10,002$93
Long return visit (40+ min)29$4,014$91
New patient visit (60+ min)16$1,634$102
Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope15$1,581$105
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes12$1,036$65
Return visit (30+ min)14$917$61
Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito15$72$5

2016: 1 service

Original Medicare services billed in 2016
New patient visit (60+ min)11$1,647$150

Medicaid work

$6,070 in 2024

Medicaid paid $6,070 for 169 billed services this clinician did in 2024, up to 15 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2024
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES156$4,839
Long return visit (40+ min)13$1,231
Medicaid work by year
2024169215$6,070
2023449322$15,252
202294114$5,167
202192213$5,313
2020141219$7,522
201994220$4,306
201813113$873
See the largest Medicaid services in earlier years

2023

Largest Medicaid services in 2023
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES377$12,701
Long return visit (40+ min)31$1,452
Return visit (30+ min)41$1,098

2022

Largest Medicaid services in 2022
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES94$5,167

2021

Largest Medicaid services in 2021
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES78$3,930
1ST HOSP IP/OBS HIGH 7514$1,382

2020

Largest Medicaid services in 2020
Long return visit (40+ min)88$4,844
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES53$2,678

2019

Largest Medicaid services in 2019
Long return visit (40+ min)51$2,193
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES43$2,113

2018

Largest Medicaid services in 2018
Long return visit (40+ min)13$873

Drugs they prescribed that Part D paid

$426,555

Pharmacies billed $426,555 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 0% of their Part D prescriptions (0 of 988) in 2024. At or below the middle of the specialty; the typical internal medicine clinician is at 1%.

839 generic and 149 brand-name prescriptions · $426,555 in drug cost · 82 antibiotic prescriptions to 16 people.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Xifaxan37$119,081$3,218
Ocaliva11$105,799$9,618
Vemlidy32$44,873$1,402
Ursodiol66$11,875$180
Tacrolimus117$11,341$97
See all 28 drugs
Every Part D drug this clinician prescribed
Xifaxan37$119,081$3,218
Ocaliva11$105,799$9,618
Vemlidy32$44,873$1,402
Ursodiol66$11,875$180
Tacrolimus117$11,341$97
Sirolimus29$8,529$294
Mycophenolate Mofetil72$7,358$102
Entecavir12$6,266$522
Vancomycin13$3,279$252
Cyclosporine Modified14$1,782$127
Budesonide Dr14$920$66
Fludrocortisone Acetate23$537$23
Gabapentin22$493$22
Pantoprazole78$470$6
Peg 3350-Electrolyte22$450$20
Spironolactone36$317$9
Furosemide33$166$5
Prednisone11$165$15
Mycophenolic Acid12$152$13
Metoprolol13$129$10
Fluconazole11$126$11
Atorvastatin13$117$9
Amlodipine Besylate28$104$4
Omeprazole13$94$7
Carvedilol25$93$4
Famotidine19$74$4
Sulfamethoxazole-Trimethoprim18$55$3
Topiramate12$31$3

Year by year

Part D prescribing by year
20249881270% (0)15%$426,555
202383196NoneNone$232,191
2022570720% (0)None$209,227
202144968None25%$212,030
2020471540% (0)30%$254,886
2019488970% (0)None$326,782
2018294890% (0)None$283,708
2017147520% (0)28%$306,673
2016107190% (0)45%$325,596
201550180% (0)52%$109,251
201462190% (0)31%$4,847
20135513NoneNone$26,759

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 28 drugs

Part D drugs prescribed in 2023
Xifaxan27$91,428$3,386
Vemlidy32$49,303$1,541
Entecavir24$12,247$510
Ursodiol36$10,614$295
Sirolimus30$10,141$338
Tacrolimus59$8,614$146
Cyclosporine Modified15$3,004$200
Mycophenolate Mofetil36$2,724$76
Lactulose25$1,082$43
Pantoprazole56$1,022$18
Gabapentin15$420$28
Alfuzosin Hcl Er13$419$32
Amlodipine Besylate23$387$17
Propranolol20$377$19
Fludrocortisone Acetate17$352$21
Carvedilol30$331$11
Azathioprine15$310$21
Furosemide22$295$13
Spironolactone33$290$9
Peg 3350-Electrolyte11$278$25
Budesonide Ec11$266$24
Famotidine15$225$15
Prednisone22$217$10
Omeprazole15$194$13
Sulfamethoxazole-Trimethoprim30$192$6
Alendronate11$149$14
Atorvastatin12$130$11
Metoprolol11$126$11

2022: 16 drugs

Part D drugs prescribed in 2022
Xifaxan32$102,590$3,206
Vemlidy27$40,191$1,489
Entecavir20$7,983$399
Ursodiol27$7,764$288
Tacrolimus45$5,964$133
Cyclosporine Modified28$3,409$122
Mycophenolate Mofetil25$1,509$60
Lactulose15$783$52
Spironolactone30$549$18
Pantoprazole51$548$11
Amlodipine Besylate22$296$13
Mirtazapine11$200$18
Carvedilol15$165$11
Furosemide37$132$4
Prednisone11$111$10
Trazodone12$4$0

2021: 12 drugs

Part D drugs prescribed in 2021
Xifaxan46$133,784$2,908
Vemlidy17$21,543$1,267
Ursodiol31$5,971$193
Tacrolimus45$4,281$95
Lidocaine12$2,502$209
Entecavir18$2,080$116
Lactulose18$1,061$59
Mirtazapine14$555$40
Spironolactone23$395$17
Furosemide35$154$4
Carvedilol17$154$9
Pantoprazole18$150$8

2020: 14 drugs

Part D drugs prescribed in 2020
Xifaxan64$167,086$2,611
Vemlidy40$47,891$1,197
Ursodiol22$6,843$311
Tacrolimus44$4,774$108
Entecavir14$1,308$93
Lactulose23$809$35
Spironolactone17$430$25
Omeprazole28$244$9
Esomeprazole Magnesium11$201$18
Furosemide22$143$7
Pantoprazole17$53$3
Alfuzosin Hcl Er13$53$4
Alendronate12$30$3
Amlodipine Besylate17$21$1

2019: 17 drugs

Part D drugs prescribed in 2019
Xifaxan54$130,430$2,415
Vemlidy35$39,663$1,133
Ursodiol16$5,157$322
Tacrolimus27$1,493$55
Lactulose34$798$23
Propranolol14$604$43
Gavilyte-G16$226$14
Peg 3350-Electrolyte13$215$17
Hydroxyzine19$209$11
Pantoprazole21$139$7
Spironolactone11$119$11
Omeprazole16$112$7
Furosemide23$96$4
Amlodipine Besylate26$68$3
Alendronate12$49$4
Glipizide12$39$3
Trazodone12$36$3

2018: 8 drugs

Part D drugs prescribed in 2018
Xifaxan36$80,561$2,238
Vemlidy13$13,905$1,070
Tacrolimus18$2,768$154
Ursodiol11$2,041$186
Lactulose21$340$16
Spironolactone15$191$13
Peg 3350-Electrolyte11$152$14
Furosemide11$33$3

2017: 2 drugs

Part D drugs prescribed in 2017
Xifaxan11$27,094$2,463
Peg 3350-Electrolyte16$202$13

2016: 3 drugs

Part D drugs prescribed in 2016
Entecavir11$10,800$982
Lactulose12$165$14
Furosemide12$34$3

2015: 1 drug

Part D drugs prescribed in 2015
Pantoprazole11$143$13

2014: 1 drug

Part D drugs prescribed in 2014
Omeprazole16$105$7

Money from drug and device companies

$34,605 in 2025

Industry payments by year
2025628$27,760$34,605
2024527$28,875$30,310
202312$6,225$6,225
202222$2,600$2,723
202111$407$407
201911None$13

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
Ipsen BiopharmaceuticalsIqirvo$13,254
8 payments
  • Meals for Iqirvo · 2025-11-08 · $146
  • Travel for Iqirvo · 2025-06-06 · $186
  • Travel for Iqirvo · 2025-06-06 · $1,184
  • Meals for Iqirvo · 2025-06-06 · $27
  • Paid to speak or teach for Iqirvo · 2025-06-06 · $8,640
  • Meals for Iqirvo · 2025-03-20 · $23
  • Paid to speak or teach for Iqirvo · 2025-03-19 · $2,880
  • Meals for Iqirvo · 2025-03-19 · $169
Mirum PharmaceuticalsLivmarli$7,612
11 payments
  • Meals for Livmarli · 2025-10-04 · $43
  • Meals for Livmarli · 2025-10-04 · $47
  • Travel for Livmarli · 2025-10-04 · $438
  • Travel for Livmarli · 2025-10-04 · $3,900
  • Travel for Livmarli · 2025-10-04 · $459
  • Travel for Livmarli · 2025-10-04 · $9
  • Travel for Livmarli · 2025-10-04 · $9
  • Meals for Livmarli · 2025-10-04 · $54
  • Travel for Livmarli · 2025-10-04 · $20
  • Consulting for Livmarli · 2025-10-04 · $2,600
  • Travel for Livmarli · 2025-10-04 · $33
Intercept PharmaceuticalsOcaliva$6,480
4 payments
  • Consulting for Ocaliva · 2025-03-03 · $540
  • Consulting for Ocaliva · 2025-03-03 · $540
  • Consulting for Ocaliva · 2025-02-21 · $2,700
  • Consulting for Ocaliva · 2025-02-21 · $2,700
Gilead SciencesNone$4,829
2 payments
  • Consulting · 2025-11-25 · $4,760
  • Meals · 2025-11-10 · $69
AmgenUplizna$2,400
2 payments
  • Consulting for Uplizna · 2025-04-08 · $1,200
  • Consulting for Uplizna · 2025-01-28 · $1,200
Mauna Kea TechnologiesNone$29
1 payment
  • Meals · 2025-07-21 · $29
See all 28 published payments
Every published payment
Gilead SciencesConsulting · 2025-11-25None$4,760
Gilead SciencesMeals · 2025-11-10None$69
Ipsen BiopharmaceuticalsMeals · 2025-11-08Iqirvo$146
Mirum PharmaceuticalsMeals · 2025-10-04Livmarli$43
Mirum PharmaceuticalsMeals · 2025-10-04Livmarli$47
Mirum PharmaceuticalsTravel · 2025-10-04Livmarli$438
Mirum PharmaceuticalsTravel · 2025-10-04Livmarli$3,900
Mirum PharmaceuticalsTravel · 2025-10-04Livmarli$459
Mirum PharmaceuticalsTravel · 2025-10-04Livmarli$9
Mirum PharmaceuticalsTravel · 2025-10-04Livmarli$9
Mirum PharmaceuticalsMeals · 2025-10-04Livmarli$54
Mirum PharmaceuticalsTravel · 2025-10-04Livmarli$20
Mirum PharmaceuticalsConsulting · 2025-10-04Livmarli$2,600
Mirum PharmaceuticalsTravel · 2025-10-04Livmarli$33
Mauna Kea TechnologiesMeals · 2025-07-21None$29
Ipsen BiopharmaceuticalsTravel · 2025-06-06Iqirvo$186
Ipsen BiopharmaceuticalsTravel · 2025-06-06Iqirvo$1,184
Ipsen BiopharmaceuticalsMeals · 2025-06-06Iqirvo$27
Ipsen BiopharmaceuticalsPaid to speak or teach · 2025-06-06Iqirvo$8,640
AmgenConsulting · 2025-04-08Uplizna$1,200
Ipsen BiopharmaceuticalsMeals · 2025-03-20Iqirvo$23
Ipsen BiopharmaceuticalsPaid to speak or teach · 2025-03-19Iqirvo$2,880
Ipsen BiopharmaceuticalsMeals · 2025-03-19Iqirvo$169
Intercept PharmaceuticalsConsulting · 2025-03-03Ocaliva$540
Intercept PharmaceuticalsConsulting · 2025-03-03Ocaliva$540
Intercept PharmaceuticalsConsulting · 2025-02-21Ocaliva$2,700
Intercept PharmaceuticalsConsulting · 2025-02-21Ocaliva$2,700
AmgenConsulting · 2025-01-28Uplizna$1,200
See earlier years (2024, 2023, 2022, 2021, 2019)

2024: $30,310

Payments by company in 2024
Mirum PharmaceuticalsLivmarli$10,630
14 payments
  • Consulting for Livmarli · 2024-09-25 · $1,540
  • Consulting for Livmarli · 2024-09-25 · $3,080
  • Consulting for Livmarli · 2024-09-25 · $193
  • Travel for Livmarli · 2024-08-03 · $56
  • Travel for Livmarli · 2024-08-03 · $9
  • Travel for Livmarli · 2024-08-03 · $40
  • Travel for Livmarli · 2024-08-03 · $36
  • Meals for Livmarli · 2024-08-03 · $119
  • Meals for Livmarli · 2024-08-03 · $116
  • Meals for Livmarli · 2024-08-03 · $70
  • Consulting for Livmarli · 2024-08-03 · $2,600
  • Travel for Livmarli · 2024-08-02 · $28
  • Meals for Livmarli · 2024-08-02 · $143
  • Consulting for Livmarli · 2024-08-02 · $2,600
Gilead SciencesLivdelzi$6,583
6 payments
  • Travel for Livdelzi · 2024-12-11 · $489
  • Consulting for Livdelzi · 2024-11-28 · $2,850
  • Meals for Livdelzi · 2024-11-14 · $58
  • Meals for Livdelzi · 2024-11-14 · $73
  • Meals for Livdelzi · 2024-11-14 · $74
  • Consulting · 2024-11-06 · $3,040
Ipsen BiopharmaceuticalsBylvay$6,532
3 payments
  • Paid to speak or teach for Bylvay · 2024-08-06 · $3,320
  • Paid to speak or teach · 2024-04-06 · $3,113
  • Travel · 2024-04-06 · $99
Intercept PharmaceuticalsOcaliva$5,965
3 payments
  • Consulting for Ocaliva · 2024-12-13 · $1,080
  • Honoraria for Ocaliva · 2024-08-09 · $4,860
  • Meals for Ocaliva · 2024-05-13 · $25
AmgenUplizna$600
1 payment
  • Consulting for Uplizna · 2024-10-01 · $600

2023: $6,225

Payments by company in 2023
Ipsen BiopharmaceuticalsNone$6,225
2 payments
  • Paid to speak or teach · 2023-12-08 · $3,320
  • Paid to speak or teach · 2023-03-13 · $2,905

2022: $2,723

Payments by company in 2022
GlaxoSmithKlineNone$2,600
1 payment
  • Consulting · 2022-10-19 · $2,600
Gilead SciencesNone$123
1 payment
  • Meals · 2022-11-06 · $123

2021: $407

Payments by company in 2021
Vertex PharmaceuticalsNone$407
1 payment
  • Consulting · 2021-06-28 · $407

2019: $13

Payments by company in 2019
Intercept PharmaceuticalsOcaliva$13
1 payment
  • Meals for Ocaliva · 2019-07-22 · $13

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
Gilead Sciences, Inc. · Direct-To-Patient Messaging for Hepatitis C Screening and Care · 2020Their institution$138,279
Gilead Sciences, Inc. · A 52-Week, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Study Intended To Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (Pbc) and An Incomplete Response Or Intolerance To Ursodeoxycholic Acid (Udca) · 2025Their institution$112,244
Intercept Pharmaceuticals, Inc. · A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of Int-787 in Subjects With Severe Alcohol Associated Hepatitis · 2025Their institution$101,386
Gilead Sciences, Inc. · A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects With Primary Sclerosing Cholangitis · 2020Their institution$66,180
Ipsen Bioscience Inc. · A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response Or Intolerance To Ursodeoxycholic Acid. (Elspire) · 2025Their institution$57,577
Gilead Sciences, Inc. · A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects With Primary Sclerosing Cholangitis · 2021Their institution$50,353
Gilead Sciences, Inc. · A 52-Week, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Study Intended To Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (Pbc) and An Incomplete Response Or Intolerance To Ursodeoxycholic Acid (Udca) · 2024Their institution$45,438
Gilead Sciences, Inc. · Direct-To-Patient Messaging for Hepatitis C Screening and Care · 2019Their institution$38,367
Gilead Sciences, Inc. · Direct-To-Patient Messaging for Hepatitis C Screening and Care · 2021Their institution$12,788
Gilead Sciences, Inc. · An Open Label Long-Term Study To Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (Pbc) · 2024Their institution$7,583
Amgen Inc. · A Phase 3, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of Inebilizumab in Participants With Autoimmune Hepatitis (Aih) · 2025This clinician$3,370
Gilead Sciences, Inc. · An 8-Week, Dose Ranging, Open Label, Randomized, Phase 2 Study With A 44-Week Extension, To Evaluate the Safety and Efficacy of Mbx-8025 in Subjects With Primary Biliary Cholangitis (Pbc) and An Inadequate Response To Or Intolerance To Ursodeoxycholic Acid · 2024Their institution$2,728
Gilead Sciences, Inc. · An Open Label Long-Term Study To Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (Pbc) · 2025Their institution$1,676

Professional record

NPI
1619104411
Licence
CA A114391California A114391: Current · expires 2028-02-29
Trained
Jefferson Medical College of Thomas Jefferson University, 2009
Video visits
Lists video visits
Gender
Female
More record details
Sole proprietor
Yes
Taxonomy
Federal specialty code 207RI0008X (207RI0008X); Internal medicine (207R00000X); Federal specialty code 207RG0100X (207RG0100X); Federal specialty code 207RT0003X (207RT0003X)
Mailing address
300 Pasteur Dr, Stanford, CA, 94305
NPI first listed
2009-06-18
NPI last updated
2026-09-03
NPI record certified
2026-09-03

This is when the NPI record was last certified, not a medical board exam.

Extra NPI addresses: 4150 Clement St, San Francisco, CA, 94121